Abstract: The invention relates to 3-(2?,2?-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and their use as a medicament intended to prevent or treat inflammatory disorders.

Abstract: The invention relates to 3-(2?,2?-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.

Abstract: This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk. The nucleic acid variant may, for example, be a single nucleotide polymorphism (SNP).

Abstract: Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic “tail groups”. Compounds as defined by formulae (I) and (I?), and the medical uses of the compounds, are described herein.

Abstract: Disclosed herein are methods of preventing or treating inflammatory diseases using 3-aminolactam compounds, each with aromatic “tail groups”. Compounds as defined by formulae (I) and (I?), and the medical uses of the compounds, are described herein.

Abstract: The invention relates to the composition and use of a medicament comprising a fixed dose combination of droloxifene and clopidogrel.

Abstract: The invention relates to methods for the discovery of new chemical entities and pharmaceutical compositions with broad-spectrum chemokine inhibitor (BSCI) activity, together with the use of such agents as anti-inflammatory medicaments. In one aspect, there is provided a method for the identification of a compound or agent with BSCI activity comprising the steps of (a) firstly one or more candidate compounds or agents are screened for binding to a somatostatin receptor such as the type 2 somatostatin receptor (sstr2); then (b) compounds or agents which show binding to the somatostatin receptor are tested for BSCI activity in a functional assay.

Abstract: The invention concerns kits and methods for the diagnosis, prognosis and monitoring of cancer. In one aspect, there is provided a method for identifying whether or not a mammal is suffering from cancer, wherein the method comprises the steps of: (a) measuring a signal due to a non-IgG immunoglobulin binding to a carbohydrate-containing antigen in a sample from the mammal; and (b) comparing the signal measured in step (a) with a signal due to the non-IgG immunoglobulin binding to the carbohydrate-containing antigen in one or more samples from one or more mammals known to have cancer and/or with a signal due to the non-IgG immunoglobulin binding to the carbohydrate-containing antigen in one or more samples from one or more healthy mammals.

Abstract: The invention relates to methods for the discovery of new chemical entities and pharmaceutical compositions with broad-spectrum chemokine inhibitor (BSCI) activity, together with the use of such agents as anti-inflammatory medicaments. In one aspect the method for the identification of a compound or agent with BSCI activity comprises the steps of: (a) firstly one or more candidate compounds or agents are screened for binding to a GPCR neuroreceptor known to be expressed on leukocytes; then (b) compounds or agents which show binding to the chosen GPCR neuroreceptor are tested for BSCI activity in a functional assay; and (c) compounds or agents which show binding to the chosen GPCR neuroreceptor are tested for classical agonist activity in a functional assay, where step (a) is completed first, but steps (b) and (c) are performed in any order, or simultaneously.

Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

Abstract: The invention relates to the use of Broad-Spectrum Chemokine Inhibitors (BSCIs), and in particular members of the acylaminolactam class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of inflammatory diseases. In particular, improved compositions consisting of BSCI agents combined with one or more additional active pharmaceutical agents in order to achieve improved anti-inflammatory efficacy with a reduced side-effect profile are described and claimed.

Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

Abstract: The invention relates to 3-(2?,2?-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.

Abstract: The invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders, and uses compounds of general formula (I) or a pharmaceutically acceptable salts thereof; wherein X is —CO—R1 or —SO2—R2, and R1 and R2 are carbonaceous substituents.

Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc.

Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of atherosclerosis/coronary heart disease.